Recently, Knowledge Ecology International sent to Congress a letter objecting to the draft “Green Paper on Unleashing American Innovation” disseminated by the National Institute of Standards and Technology (NIST) in December, 2018. The KEI letter was signed by 10 other organizations* (the Organizations). The letter, unfortunately, is full of misstatements, distortions, falsehoods and disingenuous arguments. It would be easier to focus on the letter’s one accurate statement: that high drug prices are a serious concern for people everywhere. It is very unfortunate that KEI, in my opinion, utilizes tactics which continually sacrifice fair and constructive dialog in favor of apparently achieving goals “by any means necessary.” The most disturbing element of the letter is KEI’s advocacy of inappropriate and unjustified use of government march-in rights under the Bayh-Dole Act as a purported means of controlling drug prices. In doing so KEI and the Organizations are threatening medical advances and thereby undermining their own missions.
Knowledge Ecology International Letter Misleads on March-In Rights
No Comments
Business
- IPO Top 300, 2020: Slight Decreases in Patent Grants Due to Budgets, Not COVID
- Pardon Me? Levandowski Case Highlights Need for Proactive Approach to Avoid Trade Secret Problems in Hiring
- How Patents Enable Mavericks and Challenge Incumbents
- Innovation Alliance Urges Biden Administration to Support Patent Rights
- Trade and Commerce in West Africa and How it Influences IP Rights
Recent Posts
- Balancing Innovation and Competition: Thomas Jefferson’s View of Obviousness for Mechanical Inventions
- Design Patents: Under Utilized and Overlooked
- Deciding Where to Obtain International Patent Rights
- The New Copyright Small Claims Board Presents Problems for Copyright Owners and Small Businesses
- From Home Security to VoIP: Honoring Black Women Inventors of the Last Half-Century